Vertex expects to obtain interim clinical data, including
safety and viral kinetic data, from this trial
in the second half of
2010.
"Vertex is committed to improving patient care in HCV, and the announcement of this clinical trial combining two oral agents, telaprevir and VX-222, signifies our first exploration into this combination regimen's potential role to further improve the treatment of HCV," said Peter Mueller, Ph.D.